Inhibitors against programmed cell death protein (PD)-1 and its ligand PD-L1 or collectively known as Immune checkpoint blockades (ICBs), are the most recent therapeutic options for many advanced solid malignancies, including HCC (2, 3). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.